Novartis Investigative Site

Kasugai, Aichi-ken 486-8510

0 studies enrolling now · 2 studies all time

What they study most

IgA Nephropathy, Primary IgA Nephropathy

Studies at this site

• A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy — Running, not enrolling
• Study of Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients — Completed